DOACs outperform VKAs when TAVR patients require oral anticoagulation

Michael Walter | | Cardiovascular Business | TAVR

Direct oral anticoagulants (DOACs) may be a more effective treatment option than vitamin K antagonists (VKAs) for transcatheter aortic valve replacement (TAVR) patients requiring oral anticoagulation, according to new data published in JACC: Cardiovascular Interventions.

“Despite the risk of bleeding, oral anticoagulation is recommended to reduce the risk of stroke in TAVR patients with atrial fibrillation (AFib),” wrote Romain Didier, MD, PhD, a cardiologist at Brest University Hospital in France, and colleagues. “In this setting, the choice between VKAs and DOACs is still a matter of debate because only relatively small observational studies are available and led to conflicting findings. In the most recent guidelines, the use of VKA is favored in patients with AFib in the first three months after TAVR.”

Hoping to shed new light on the debate between DOACs and VKAs, Didier et al. examined data from more than 24,000 TAVR patients treated in French TAVR centers from 2010 to 2017. All data came from the FRANCE-2 and France-TAVI registries.

Overall, more than 36% of TAVR patients required oral anticoagulation. More than 24% of those patients were treated with DOACs, and the remaining patients received VKAs.

After three years, DOACs were associated with lower rates of mortality and major bleeding, including hemorrhagic stroke, compared to VKAs. The rates of ischemic stroke and acute coronary syndrome, meanwhile, was similar between the two groups.

“This large nationwide analysis further confirms the increased risk of bleeding and mortality in TAVR patients when they need to be treated with oral anticoagulation,” the authors wrote. When oral anticoagulation is indicated, DOACs are associated with improved survival and lower incidence of bleeding compared with VKAs.”

These findings do need to be confirmed in large randomized trials, the team added, before they are used to guide specific treatment decisions.

Read the full study here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution
Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes
TAVR specialists come together to explore new data, patient selection and much more
Heart surgeons perform world’s first robotic TAVR explant and aortic valve replacement
Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement
Heart patients benefit when cardiologists follow a standardized TAVR protocol

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.